USA flag logo/image

An Official Website of the United States Government

LIVE CELL APOPTOSIS ASSAY FOR HIGH-THROUGHPUT SCREENING

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
53783
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43CA086580-01A1
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MARKER GENE TECHNOLOGIES, INC
1850 MILLRACE DRIVE 1850 MILLRACE DRIVE EUGENE, OR 97403 1992
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2001
Title: LIVE CELL APOPTOSIS ASSAY FOR HIGH-THROUGHPUT SCREENING
Agency: HHS
Contract: N/A
Award Amount: $97,406.00
 

Abstract:

DESCRIPTION (Applicant's Abstract): This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new compounds capable of measuring initial stages of apoptosis induction in living cells and tissues. If successful, the proposed research will provide breakthroughs needed to advance the discovery of promising new apoptosis modulating drugs for medical applications. In Phase I of this project, Marker Gene Technologies, Inc. proposes to establish the feasibility of the technology by preparing new fluorogenic peptidase substrates for the Caspase family of enzymes, for administration to living cells or tissues that either have been induced to initiate apoptosis or are of disease interest. These new substrates and the resulting detection systems will provide innovative methods to quantitate apoptosis induction and to screen for the influence of secondary drug or treatment administration. In Phase I, the new substrates will be assayed in vitro for their ability to measure specific and localized inhibition or induction of apoptosis in living cells and to do so in a cell- or tissue-specific manner. In Phase II, the substrates will be further tested as an analytical tool in vivo and in a variety of significant medical applications. PROPOSED COMMERCIAL APPLICATION: The success of this project opens up enormous commercial possibilities in the field of medical intervention in proliferative diseases such as cancer and degenerative diseasess such as Alzheimer's disease, screening of new proteins and drugs in cell-culture systems for efficacy in modulating apoptosis, and general new peptidase detection strategies. In addition, it will lead to licensable products in these areas.

Principal Investigator:

John J. Naleway

Business Contact:


5033441624
ALISANALEWAY@HOTMAIL.COM
Small Business Information at Submission:

MARKER GENE TECHNOLOGIES
3247 LINCOLN ST EUGENE, OR 97405

EIN/Tax ID: 931228900
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No